Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06312176 | A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | recruiting | Phase 3 | 1,200 | Merck Sharp & Dohme LLCINDUSTRY | 40 | Sep 25, 2026 | clinicaltrials |
| NCT06377852 | The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | recruiting | Phase 3 | 500 | American Society of Clinical OncologyOTHER | 1 | Sep 25, 2026 |
| clinicaltrials |
| NCT06393374 | Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | recruiting | Phase 3 | 1,530 | Merck Sharp & Dohme LLCINDUSTRY | 31 | Sep 25, 2026 | clinicaltrials |
| NCT06447623 | Apatinib Combined With cdk4/6i in First-line Treatment for HR+/HER2- SNF4 Subtype Breast Cancer | active not recruiting | Phase 3 | 184 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06721065 | A Study of Language Interpretation Solutions for People With Breast Cancer | recruiting | N/A | 700 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06841354 | A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | recruiting | Phase 3 | 1,000 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 25, 2026 | clinicaltrials |
| NCT06855524 | Fucoidan for Preventing Chemotherapy-Related Fatigue in Patients With Gastrointestinal, Gynecological, Breast, or Lung Cancer | recruiting | Phase 2 | 34 | Mayo ClinicOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06966700 | A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | recruiting | Phase 3 | 2,400 | Merck Sharp & Dohme LLCINDUSTRY | 40 | Sep 25, 2026 | clinicaltrials |
| NCT07007559 | ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer(ASPEN-09-03) | recruiting | Phase 2 | 120 | ALX Oncology Inc.INDUSTRY | 8 | Sep 25, 2026 | clinicaltrials |
| NCT07054190 | A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer | recruiting | Phase 2 | 120 | Hoffmann-La RocheINDUSTRY | 7 | Sep 25, 2026 | clinicaltrials |
| NCT07066189 | Lifestyle, Exercise, And Nutrition (LEAN) Trial on Pathologic Complete Response in TNBC | recruiting | N/A | 160 | Yale UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07179809 | Group-based Comprehensive Lifestyle Program for Women With Metastatic Breast Cancer | recruiting | N/A | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07419880 | Re-challenge Immunotherapy With Cromolyn, TQB2102, and Panpulimab in Immune-Refractory Triple Negative Breast Cancer(RECLAIM) | not yet recruiting | Phase 2 | 46 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07832279 | 1-Week Versus 3-Week PBI | recruiting | N/A | 818 | Fudan UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840534 | Patient-Initiated Follow-Up for Women After Early Breast Cancer Treatment (LYSA2PIFU)(LYSA2PIFU) | not yet recruiting | N/A | 30 | University College CorkOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07840599 | Fit2ThriveMB: Optimization of a Physical Activity Promotion Intervention for Metastatic Breast Cancer Patients(Fit2ThriveMB) | not yet recruiting | N/A | 224 | Northwestern UniversityOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07841704 | NAUTILUS-04: No Axillary Surgical Treatment in Low-Risk Clinically Node-Negative Breast Cancer Without Whole-Breast Radiotherapy - A Prospective, Randomized, Phase III, Non-inferiority Clinical Trial(NAUTILUS-04) | not yet recruiting | N/A | 1,520 | Wonshik HanOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT07843212 | EFFECTS OF SPSIP BLOCK ON PERIOPERATİVE INFLAMMATION AND TLR4 IN BREAST CANCER SURGERY(SPSIP-TLR4) | recruiting | N/A | 80 | Mucahide Emine Fidancı KuasOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT00295893 | Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer | active not recruiting | Phase 2 | 121 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT02293954 | Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer | active not recruiting | N/A | 20 | City of Hope Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03573648 | Neoadjuvant Endocrine Therapy, Palbociclib, Avelumab in Estrogen Receptor Positive Breast Cancer(ImmunoADAPT) | active not recruiting | Phase 2 | 33 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03716180 | DAPHNe: Paclitaxel/Trastuzumab/Pertuzumab in HER2-Positive BC | active not recruiting | Phase 1 | 100 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT03927768 | Abbreviated Breast MRI (AB-MRI) With Golden-angle Radial Compressed-sensing and Parallel Imaging (GRASP) | active not recruiting | — | 264 | NYU Langone HealthOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04584255 | Niraparib + Dostarlimab In BRCA Mutated Breast Cancer | active not recruiting | Phase 2 | 66 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05412225 | A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05708235 | A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population(MiRaDoR) | active not recruiting | Phase 2 | 976 | MedSIROTHER | 2 | Sep 24, 2026 | clinicaltrials |
| NCT05898789 | Virtual Rehabilitation for Cancer Survivors | recruiting | N/A | 388 | University Health Network, TorontoOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT05959291 | Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer(Free-HER) | active not recruiting | N/A | 20 | University of MiamiOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06018337 | A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | active not recruiting | Phase 3 | 541 | DualityBio Inc.INDUSTRY | 17 | Sep 24, 2026 | clinicaltrials |
| NCT06179303 | Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer | recruiting | Phase 2 | 60 | University of WashingtonOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06251544 | TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer | recruiting | Phase 1 | 27 | Baylor College of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT06522568 | Testing a Mammography Decision Intervention in a Rural Setting | recruiting | N/A | 39 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07407920 | Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial | recruiting | Phase 2 | 120 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07408856 | CAN1012 in Pre-Malignant DCIS and LCIS | recruiting | Phase 1 | 24 | Providence Health & ServicesOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07595718 | AI-Based Phenome Data Analysis for Predicting the Onset of Major Diseases | recruiting | — | 1,000 | Jae Yong Jeon, MDOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT07838649 | Positron Emission Tomography (PET) Imaging of Chemotherapy-Induced Cardiotoxicity | not yet recruiting | Phase 1 | 36 | Washington University School of MedicineOTHER | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04040569 | A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer | active not recruiting | Phase 1 | 45 | University of Texas Southwestern Medical CenterOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04144907 | Protein Needs Study | recruiting | N/A | 40 | University of AlbertaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04222413 | Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors | recruiting | Phase 1 | 116 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04400695 | A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2 | recruiting | Phase 3 | 366 | RemeGen Co., Ltd.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04715958 | SHAPE Neoadjuvant Chemotherapy Response | active not recruiting | Phase 2 / Phase 3 | 122 | Kibo NamOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT04989504 | Testing the Application of Mepitel Film During Radiation Therapy to Reduce Radiation Related Redness and Peeling in Breast Cancer Patients Following Mastectomy | active not recruiting | Phase 3 | 216 | Alliance for Clinical Trials in OncologyOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06253520 | Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer | active not recruiting | Phase 1 | 210 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06534918 | Precise Oncology Interventions in Nutrition and Training (OnPoint)(OnPoint) | recruiting | N/A | 306 | University of MiamiOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06618287 | A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 416 | Bristol-Myers SquibbINDUSTRY | 10 | Sep 23, 2026 | clinicaltrials |
| NCT06633276 | Fast and Accurate Breast Cancer Diagnosis Using Nanopore Sequencing in Tanzania (Fast-ABCD Sequencing) | recruiting | — | 100 | University of BonnOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06999798 | An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast Cancer, The UTMOST2 Trial | recruiting | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07085767 | Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer(OPERA-02) | recruiting | Phase 3 | 1,000 | Olema Pharmaceuticals, Inc.INDUSTRY | 23 | Sep 23, 2026 | clinicaltrials |
| NCT07185568 | IntraOperative UltraSound Guided vs Wire Guided vs Magnetic Seed Guided Breast-Conserving Surgery for Non-palpable Tumors(MANOLA) | not yet recruiting | N/A | 1,302 | Istituto Oncologico Veneto IRCCSOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07214532 | Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer(SIGNAL-ER 101) | recruiting | N/A | 725 | Natera, Inc.INDUSTRY | 1 | Sep 23, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 25, 2026source: clinicaltrials